HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.

Abstract
The Wilms tumor gene, WT1, is overexpressed not only in leukemias and myelodysplastic syndrome (MDS) but also in various types of solid tumors, including lung and breast cancer, and the WT1 protein is a tumor antigen for these malignancies. In clinical trials of WT1 peptide-based cancer immunotherapy, patients with overt leukemia from MDS or MDS with myelofibrosis were injected intradermally with 0.3 mg of an HLA-A*2402-restricted, 9-mer WT1 peptide emulsified with Montanide ISA51 adjuvant. Only a single dose of WT1 vaccination resulted in an increase in WT1-specific cytotoxic T-lymphocytes, which was followed by a rapid reduction in leukemic blast cells. Severe leukopenia and local erythema at the injection sites of WT1 peptide were observed as adverse effects. These results have provided us with the first clinical evidence suggesting that WT1 peptide-based immunotherapy is an attractive treatment for patients with leukemias or MDS.
AuthorsYoshihiro Oka, Akihiro Tsuboi, Masaki Murakami, Manabu Hirai, Nobuhiko Tominaga, Hiroko Nakajima, Olga A Elisseeva, Tomoki Masuda, Akiko Nakano, Manabu Kawakami, Yusuke Oji, Kazuhiro Ikegame, Naoki Hosen, Keiko Udaka, Masaki Yasukawa, Hiroyasu Ogawa, Ichiro Kawase, Haruo Sugiyama
JournalInternational journal of hematology (Int J Hematol) Vol. 78 Issue 1 Pg. 56-61 (Jul 2003) ISSN: 0925-5710 [Print] Japan
PMID12894852 (Publication Type: Case Reports, Clinical Trial, Clinical Trial, Phase I, Journal Article)
Chemical References
  • Antigens, Neoplasm
  • HLA-A Antigens
  • Peptide Fragments
  • WT1 Proteins
Topics
  • Aged
  • Antigens, Neoplasm (administration & dosage, therapeutic use)
  • Female
  • HLA-A Antigens (administration & dosage, therapeutic use)
  • Humans
  • Immunotherapy (methods)
  • Leukemia (etiology, pathology, therapy)
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes (pathology)
  • Peptide Fragments (administration & dosage, immunology, therapeutic use)
  • Primary Myelofibrosis (pathology)
  • Treatment Outcome
  • Vaccination
  • WT1 Proteins (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: